Drugs / bamosiran
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00990743 | Sep 2009 → Jun 2010 | glaucoma, ocular hypertension | Sylentis, S.A. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01227291 | Oct 2010 → Mar 2012 | glaucoma, ocular hypertension | Sylentis, S.A. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02250612 | Oct 2014 → Aug 2015 | ocular hypertension, open-angle glaucoma | Sylentis, S.A. | Completed | No outcome recorded |
| Phase 2 | NCT01739244 | Jul 2012 → May 2013 | ocular hypertension, open-angle glaucoma | Sylentis, S.A. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bamosiran | “1 drop of 0.375% SYL040012 (bamosiran)” NCT02250612 ↗ |
| Known as | SYL040012 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01227291 ↗ |
| Route | Other | “in ophthalmic drops solution” NCT00990743 ↗ |